DiaCarta Receives CE-IVD for its Non-Invasive Colorectal Cancer Test – ColoScape™ Real-Time PCR Kit
DiaCarta today announced it received CE-IVD approval for its innovative new colorectal cancer test, ColoScapeTM, a colorectal cancer mutation detection kit. Designed to aid colorectal cancer (CRC) diagnosis, ColoScapeTM offers high sensitivity and accuracy of detection for clinically validated CRC mutations in DNA extracted from solid tumor, plasma or stool samples.
Approved for in vitro diagnostic use in Europe, ColoScapeTM utilizes DiaCarta’s patented XNA-based clamping technology to detect 20 proprietary DNA mutation markers from 4 oncogenes with unprecedented sensitivity. Study data generated by the company and its collaborators identified greater than 95% of stage I-IV colorectal cancer cases correctly and demonstrated improved sensitivity as a pre-cancer diagnostic. ColoScapeTM can run on a variety of commonly-used real-time PCR platforms utilizing kits that leverage proprietary multiplexed TaqMan chemistry to complete the assay in less than 2.5 hours with as little as 20 ng of DNA from formalin-fixed, paraffin embedded (FFPE) tumor, plasma or stool samples.
“CE-IVD approval for ColoScapeTM kit means we can offer clinicians the ability to screen for CRC mutations from patient samples with the highest level of performance that the clinical setting demands,” said Aiguo Zhang, Ph.D., CEO of DiaCarta. “This is an innovative product application from our flagship QClamp® XNA technology platform. Our goal is to expand the global reach of this best-in-class clinical product with additional regulatory filings planned later this year and into 2018.”
DiaCarta also announced the launch of its CE-IVD approved QFusionTM ALK Fusion Gene Detection kit. QFusionTM ALK is designed to overcome the barriers of the current “gold standard” FISH technique by detecting as low as 50 fusion templates in each single reaction.
About DiaCarta, Inc.
DiaCarta is an innovative precision molecular diagnostic company headquartered in Richmond, California. The company has an ISO 13485-certified facility, which is used to develop, manufacture and market a range of cancer research and IVD products. DiaCarta specializes in genomic testing for biomarkers and offers clinical sample testing services in a CLIA-certified laboratory. In addition, the company has a clinical service laboratory in Nanjing, China. QClamp® and OptiSeqTM are patented xeno nucleic acid (XNA) based technologies that enable highly sensitive detection of actionable mutations using qPCR and next-generation sequencing (NGS) platforms on challenging patient specimens. Other XNA applications include CRISPR/Cas9 gene-editing event screening and adapter dimer removal for NGS library preparation. To learn more, visit https://www.diacarta.com.
DiaCarta Receives Accreditation by the College of American Pathologists (CAP)
DiaCarta, Ltd. (“DiaCarta”), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received accreditation by the College of American Pathologists (CAP) for its CLIA certified lab. This accreditation is awarded to facilities that meet the high standards of quality, accuracy, and consistency in laboratory services required by CAP and underscores DiaCarta’s leadership and commitment to excellence.
DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023
DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023.
DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit
DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its QuantiVirus™ MPXV test, which is a PCR test for the qualitative detection of DNA from monkeypox virus (MPXV) in lesion swabs collected from individuals suspected of monkeypox infection.
DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience
DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, and Nonagen Bioscience Corporation (“Nonagen”), a cancer diagnostics company, today announced the successful completion of the validation study of Oncuria® multiplex bladder cancer immunoassay as a laboratory developed test (“LDT”). DiaCarta also announced that it has begun receiving patient urine samples for testing in its CLIA certified lab in Pleasanton, California.
DiaCarta to Become a Publicly Listed Company Through Merger with HH&L Acquisition Co.
DiaCarta, Ltd., a precision molecular diagnostics company and developer of novel oncology and infectious disease tests, and HH&L Acquisition Co. (NYSE: HHLA.U, HHLA, HHLA WS) (“HH&L”), a publicly traded special purpose acquisition company (“SPAC”), today announced that they entered into a definitive business combination agreement (the “Business Combination Agreement”) that is expected to result in DiaCarta becoming a publicly listed company (the “Transaction” or “Business Combination”). The Transaction is expected to provide DiaCarta with access to the approximately $414 million cash from HH&L’s IPO proceeds held in trust, assuming no redemptions by HH&L’s shareholders and prior to the payment of transaction expenses, and potential additional financing to catalyze DiaCarta’s growth. The Transaction implies a pre-money equity value of $460 million for DiaCarta on a fully diluted basis and is expected to close in the first quarter of 2023. The Transaction positions DiaCarta to capitalize on significant future growth within existing and new markets.